Abstract 4359809: Effect of Subcutaneous (SC) Injection of Furosemide Compared with Intravenous (IV) Injection on Vital Signs in Healthy Volunteers

Introduction: Furosemide (FUR) remains the cornerstone agent to decongest patients with heart failure. Given the challenges associated with intravenous (IV) administration, an 80mg/10mL buffered formulation has been developed (Furoscix) to be administered subcutaneously (SC) over a period of 5 hours. This has demonstrated similar bioavailability and clinical efficacy to FUR IV with minimal impact on blood pressure (BP) and heart rate (HR). SCP-111 (FUR SC) is a novel SC injection FUR formulation in development with a concentration of 80mg/mL, and demonstrated similar bioavailability, diuretic, and natriuretic effects to FUR IV. However, its potential effects on BP and HR remain unknown. Methods: Randomized, open-label, single-center, crossover study. Healthy volunteers were randomized 1:1 to either receive 80mg FUR IV given as two 40mg boluses separated by two 2 hours first or FUR SC 80 mg/mL as SC injection over 10 seconds. Systolic BP (SBP), diastolic BP (DBP), and HR were monitored at set time points for 12 hours and changes from baseline were calculated. Following a 3-day washout period, individuals received the opposite treatment, and the same evaluation was completed. Results: The mean±SD baseline SBP and DBP for the FUR SC and FUR IV groups were 123±13 / 78±8 vs. 124±17 / 78± 9mmHg. Baseline HR were 69±9 and 69±10bpm, respectively indicating no difference between the groups. Mean change in SBP over the 12-hour follow-up ranged from -1.8 to -10.3mmHg for FUR SC and 1.5 to -11.3mmHg for FUR IV. The mean change in DBP ranged from 1.8 to -4.0mmHg for FUR SC and 5.5 to -3.7mmHg for FUR IV. The mean change in heart rate over the follow-up period ranged from 2.2 to -5.3bpm for FUR SC and 7.5 to -2.3bpm for FUR IV (Figure 1) . Conclusion: There were no clinically meaningful changes in blood pressure and heart rate over the 12-hour monitoring period in response to either FUR SC or FUR IV. Furosemide 80mg/mL administered as a SC injection was safe with regards to its effects on BP and HR and may become a potential alternative to IV furosemide in the near future.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4359809
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4359809: Effect of Subcutaneous (SC) Injection of Furosemide Compared with Intravenous (IV) Injection on Vital Signs in Healthy Volunteers

Barbara Cornelius, Tamás Alexy, Phani Kamineni, John Mohr et al.
Circulation
Heart Failure Treatment and Management
article

Abstract 4359809: Effect of Subcutaneous (SC) Injection of Furosemide Compared with Intravenous (IV) Injection on Vital Signs in Healthy Volunteers

Barbara Cornelius, Tamás Alexy, Phani Kamineni, John Mohr, Sara Tan
article en

Abstract

Introduction: Furosemide (FUR) remains the cornerstone agent to decongest patients with heart failure. Given the challenges associated with intravenous (IV) administration, an 80mg/10mL buffered formulation has been developed (Furoscix) to be administered subcutaneously (SC) over a period of 5 hours. This has demonstrated similar bioavailability and clinical efficacy to FUR IV with minimal impact on blood pressure (BP) and heart rate (HR). SCP-111 (FUR SC) is a novel SC injection FUR formulation in development with a concentration of 80mg/mL, and demonstrated similar bioavailability, diuretic, and natriuretic effects to FUR IV. However, its potential effects on BP and HR remain unknown. Methods: Randomized, open-label, single-center, crossover study. Healthy volunteers were randomized 1:1 to either receive 80mg FUR IV given as two 40mg boluses separated by two 2 hours first or FUR SC 80 mg/mL as SC injection over 10 seconds. Systolic BP (SBP), diastolic BP (DBP), and HR were monitored at set time points for 12 hours and changes from baseline were calculated. Following a 3-day washout period, individuals received the opposite treatment, and the same evaluation was completed. Results: The mean±SD baseline SBP and DBP for the FUR SC and FUR IV groups were 123±13 / 78±8 vs. 124±17 / 78± 9mmHg. Baseline HR were 69±9 and 69±10bpm, respectively indicating no difference between the groups. Mean change in SBP over the 12-hour follow-up ranged from -1.8 to -10.3mmHg for FUR SC and 1.5 to -11.3mmHg for FUR IV. The mean change in DBP ranged from 1.8 to -4.0mmHg for FUR SC and 5.5 to -3.7mmHg for FUR IV. The mean change in heart rate over the follow-up period ranged from 2.2 to -5.3bpm for FUR SC and 7.5 to -2.3bpm for FUR IV (Figure 1) . Conclusion: There were no clinically meaningful changes in blood pressure and heart rate over the 12-hour monitoring period in response to either FUR SC or FUR IV. Furosemide 80mg/mL administered as a SC injection was safe with regards to its effects on BP and HR and may become a potential alternative to IV furosemide in the near future.

CirculationVol. 152(Suppl_3)
University of Minnesota System (US), scPharmaceuticals (United States) (US)
Openalex Percentile: Top 51%
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.